Verrica Pharmaceuticals Inc Verrica (NASDAQ: VRCA) Stock Down 56% as FDA Decides Not to Authorize Viral Skin Disease Drug VP-102 Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) stock has plummeted 56% after the company confirmed that it has received a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for VP-102
STAAR Surgical Company STAAR (NASDAQ: STAA) Gain 17% as FDA Approves Implantable Lenses EVO for Myopia STAAR Surgical Company (NASDAQ: STAA) confirmed that FDA has awarded authorization to the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the treatment of myopia and myopia with astigmatism. Myopia,
Provention Bio Inc Provention (NASDAQ: PRVB) Announces Teplizumab is Clear for Resubmission Provention Bio, Inc. (NASDAQ: PRVB) disclosed that FDA gave the green signal regarding the resubmission of Teplizumab. On January 27, 2022, the company revealed that it has decided to resubmit
FREYR Battery FREYR (NYSE: FREY) Develop Program for Environmental Impact Assessment FREYR Battery (NYSE: FREY) disclosed that it has designed a program for the Environmental Impact Assessment (EIA) and presented its proposal to Finland’s Centre for Economic Development, Transport, and
Burning Rock Biotech Limited Burning Rock (NASDAQ: BNR) Announces Partnership with IMPACT Therapeutics Burning Rock Biotech Limited (NASDAQ: BNR) disclosed that it has inked a partnership agreement with IMPACT Therapeutics. As per the partnership, Burning Rock offers testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064.
Soligenix Inc Soligenix (NASDAQ: SNGX) is Soaring today. Here’s Why Soligenix, Inc. (NASDAQ: SNGX) has disclosed that the Office of Orphan Products Development of the U.S. FDA has awarded orphan drug designation to the active ingredient hypericin for the cure of T-cell lymphoma.
Alzamend Neuro Inc Alzamend (NASDAQ: ALZN) Submit Pre-IND Request for AL002 to FDA for Alzheimer’s Alzamend Neuro, Inc. (NASDAQ: ALZN) disclosed on Friday that the firm has presented a pre-IND request for AL002 and supporting briefing documents to the Center for Biological Evaluation and Research of the U.S. FDA.
Jazz Pharmaceuticals Plc Jazz Pharmaceutical (NASDAQ: JAZZ) Receives FDA Approval for Rylaze Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) disclosed that it has got the authorization of the US FDA for Rylaze. Jazz is allowed to Rylaze as an integral part of a multi-agent chemotherapeutic program.
Conformis Inc Conformis (NASDAQ: CFMS) Gets Green Signal for Identity Imprint Knee Replacement System Shares of Conformis, Inc. (NASDAQ: CFMS) skyrocketed 7.23% during the trading session of Monday. The firm disclosed that it has got the green signal from the U.S. FDA for the firm’s Identity Imprint Knee Replacement System.
Motus GI Holdings Inc Motus GI (NASDAQ: MOTS) Receives FDA’s Green Signal to Market Pure-Vu System Motus GI Holdings, Inc. (NASDAQ: MOTS) declared that FDA has provided the green signal to the firm for the marketing of the Pure-Vu System.
Uber Technologies Inc Uber (NYSE: UBER) Join Hands with empowerDX Uber Technologies, Inc. (NYSE: UBER) and empowerDX disclosed Monday that they have joined hands to deliver FDA-emergency use authorized, at-home COVID-19 testing kits to consumers via on-demand delivery.
Gilead Sciences Gilead (NASDAQ: GILD) Gets Approval for Trodelvy in Urothelial Cancer Gilead Sciences Inc. (NASDAQ: GILD) disclosed that it has got the authorization from FDA for Trodelvy (sacituzumab govitecan-hziy) for use in grownup sufferers with locally developed or metastatic urothelial cancer (UC).
Sorrento Therapeutics Inc Sorrento’s (NASDAQ: SRNE) Subsidiary Scilex Gets an sNDA Approval for ZTlido Sorrento Therapeutics, Inc. (NASDAQ: SRNE) disclosed that Scilex Holding has got a supplemental new drug application (sNDA) authorization from the FDA for ZTlido. Scilex is the 99% owned unit of Sorrento Therapeutics.
AbbVie Inc AbbVie (NYSE: ABBV) Announces FDA Extended Review Period for Upadacitinib’s NDA AbbVie Inc. (NYSE: ABBV) declared that FDA has made the decision regarding the supplemental New Drug Application (sNDA) for upadacitinib. FDA has decided that it will extend the review period for sNDA for upadacitinib.
Bristol-Myers Squibb Company (BMY) FDA Approves Bristol Myers (NYSE: BMY) Mavacamten NDA for Review Bristol-Myers Squibb Company (NYSE: BMY) disclosed Friday that FDA has acknowledged the New Drug Application (NDA) of Mavacamten. FDA has decided to review the NDA of Mavacamten which is an investigational drug for the cure of the cardiac condition.
Regeneron Pharmaceuticals Inc Regeneron (NASDAQ: REGN) And Sanofi’s Dupixent Accepted For Review By FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) revealed on Thursday that FDA has awarded the authorization to Dupixent as an add-on cure for moderate-to-severe asthma.
AstraZeneca PLC AstraZeneca (NASDAQ: AZN) Dump 7.7% Stake In Moderna Inc (NASDAQ: MRNA) AstraZeneca Plc (NASDAQ: AZN) disclosed that it has dumped 7.7% stakes in US biotechnology firm Moderna Inc. AZN has dumped the holdings of Moderna Inc (NASDAQ: MRNA) for more than $1 billion.
Biofrontera AG Why Biofrontera (NASDAQ: BFRA) Stock Is Crashing Today? BFRA has declared the pricing of a U.S. underwritten public offering of 1,334,002 ADS at an offering price of $6.68 per ADS. Each ADS denotes two of BFRA’s ordinary shares, a minimal value of €1.00 per share.
Celsion Corporation Celsion Corporation (NASDAQ: CLSN) Gets FDA Fast Track Designation for GEN-1 Celsion Corporation (NASDAQ: CLSN) has disclosed that US FDA has granted the firm’s GEN-1 Fast Track Designation.
Dr. Reddy's Laboratories Limited Dr. Reddy’s (NYSE: RDY) Introduces Fluphenazine Hydrochloride Tablets Dr. Reddy’s Laboratories Limited (NYSE: RDY) has introduced the Fluphenazine Hydrochloride Tablets, USP is US markets. The tablets are authorized by FDA.
Pfizer Inc. (PFE) Pfizer-BioNTech To Deliver Additional 200M Doses Of COMIRNATY Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) revealed that the firms have signed an agreement with the European Commission (EC). As per the deal, the firms will deliver additional 200 million doses of COMIRNATY
Aurinia Pharmaceuticals Inc (AUPH) Aurinia Pharmaceuticals (NASDAQ: AUPH) Receive FDA Approval For LUPKYNIS Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) disclosed that it has received the FDA authorization for LUPKYNIS™ (voclosporin). To treat Lupus Nephritis, LUPKYNIS is the first oral therapy that has got the endorsement of the FDA to treat adult sufferers with active lupus nephritis.
Adamis Pharmaceuticals Corporation (ADMP) Adamis Pharmaceuticals (NASDAQ: ADMP) Submitted IND To FDA For Tempol Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has disclosed that it has submitted the Investigational New Drug (IND) application to FDA for Tempol. The purpose of this IND is to get authorization for the use of Tempol to cure the COVID-19 patients.
Neovasc Inc (NVCN) Neovasc (NASDAQ: NVCN) Announces FDA Rejection Of Neovasc Reducer Neovasc Inc. (NASDAQ: NVCN) disclosed that the FDA has rejected the Pre-Market Approval regarding its Neovasc Reducer™. FDA has assessed the Reducer for the treatment of patients with refractory angina pectoris.
$TNXP Tonix Pharmaceuticals (NASDAQ: TNXP) Reports Encouraging Results In TNX-102 Study Tonix Pharmaceutical Holding Corp. (NASDAQ: TNXP) has disclosed the positive results in the Phase III RELIEF study evaluating TNX-102 SL in fibromyalgia. RELIEF was 14 weeks study in which 503 victims with fibromyalgia were enrolled. In the first two weeks, all the victims have
